Press Releases July 16, 2026 08:30 AM

Gevo Announces Appointment of Todd Werpy to Board of Directors

Gevo strengthens leadership with appointment of biotech innovator Todd Werpy to Board of Directors

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
GEVO

Gevo, Inc., a leader in renewable fuels and sustainable technologies, announced the appointment of Dr. Todd Werpy to its Board of Directors. Werpy brings extensive experience in biotechnology, process engineering, and commercialization from his previous role at Archer-Daniels-Midland Company. His leadership is expected to support Gevo's growth in low-carbon fuels, renewable chemicals, and carbon management, strengthening their technological and operational capabilities.

Gevo Announces Appointment of Todd Werpy to Board of Directors
GEVO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Appointment of Todd Werpy, an experienced biotech and sustainability leader, to Gevo's Board of Directors.
  • Werpy’s expertise includes scaling technology, advanced manufacturing, and innovation in bio-based technologies, supporting Gevo's growth in renewable energy and chemicals.
  • Gevo's continued focus on sustainable aviation fuel, renewable natural gas, and carbon capture aligns with global energy and environmental priorities, impacting renewable energy and chemicals sectors.

ENGLEWOOD, Colo., July 16, 2026 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO), a leader in renewable fuels, chemicals and carbon management, today announced the appointment of Todd Werpy, Ph.D. to its Board of Directors. Werpy brings more than three decades of innovation and executive leadership experience spanning sustainable technologies, global research and development, manufacturing operations, and enterprise transformation.

“Todd is a highly respected leader whose unique combination of scientific expertise, operational discipline and commercial execution will be a tremendous asset to Gevo,” said Gevo Chief Executive Officer Paul Bloom. “As we continue to build our business focused on low-carbon fuels, renewable chemicals, carbon management, and sustainable growth, we believe Todd’s experience scaling technology, modernizing operations and transforming complex manufacturing organizations will strengthen our Board and help guide Gevo’s next phase of value creation.”

A recognized scientist, innovator and business leader, Werpy most recently served as Chief Science Officer and a member of the Executive Committee at Archer-Daniels-Midland Company (ADM) where he helped build a strong technology pipeline that generated significant enterprise value through innovation, commercialization and strategic partnerships. He also was an executive leader supporting modernization programs involving automation, advanced process controls and analytics that delivered significant returns while improving productivity, reliability and sustainability. His expertise spans biotechnology, catalysis, process engineering and commercialization of bio-based technologies.

“Gevo has built a strong foundation of technologies, assets and capabilities that can help address some of the most important challenges facing markets today,” said Werpy. “I am honored to join the Board and look forward to working alongside my fellow directors and the management team to support Gevo’s continued growth and long-term success.”

Werpy holds a Ph.D. in Inorganic Chemistry from Michigan State University and is a graduate of the Harvard Business School Executive Leadership Program. He holds 36 U.S. patents and more than 100 patents globally and is the recipient of the American Chemical Society’s Green Chemistry Award. He is also widely recognized as a co-author of the U.S. Department of Energy report, Top 12 Value-Added Chemicals from Biomass.

The addition of Todd Werpy to the Gevo Board of Directors is effective August 20.

About Gevo

Gevo is a next-generation diversified energy company committed to fueling America’s future with cost-effective, drop-in fuels that contribute to energy security, abate carbon, and strengthen rural communities to drive economic growth. Gevo’s innovative technology can be used to make a variety of renewable products, including sustainable aviation fuel (SAF), motor fuels, chemicals, and other materials that provide U.S.-made solutions. Gevo’s business model includes developing, financing, and operating production facilities that create jobs and revitalize communities. Gevo owns and operates an ethanol plant with an adjacent carbon capture and storage (CCS) facility and Class VI carbon-storage well. Gevo also owns and operates one of the largest dairy-based renewable natural gas (RNG) facilities in the United States, turning by-products into clean, reliable energy. Additionally, Gevo developed the world’s first production facility for specialty alcohol-to-jet (ATJ) fuels and chemicals operating since 2012. Gevo is currently developing the world’s first large-scale ATJ facility to be co-located at our North Dakota site. Gevo’s market-driven “pay-for-performance” approach regarding carbon and other sustainability attributes helps deliver value to our local economies. Through its Verity subsidiary, Gevo provides transparency, accountability, and efficiency in tracking, measuring, and verifying various attributes throughout the supply chain. By strengthening rural economies, Gevo is working to secure a self-sufficient future and to make sure value is brought to the market.

For more information, please go to www.gevo.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, without limitation, including the appointment of Todd Werpy, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Media Contact
[email protected]

IR Contact
[email protected]


Risks

  • Uncertainty in execution of growth and technology scaling strategies despite board enhancement.
  • Market and regulatory risks related to renewable fuels and carbon management industries, which may affect Gevo's business performance.
  • Dependence on successful commercialization and adoption of low-carbon fuels and sustainable technologies amid competitive and policy environments.

More from Press Releases

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM Aug 30, 2026 Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 Aug 29, 2026 Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 Aug 29, 2026 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity Aug 28, 2026 Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update Aug 28, 2026